Trillium Therapeutics (TRIL) – StreetInsider.com Reports
-
Benchmark Downgrades Trillium Therapeutics (TRIL) to Hold
-
Increasing unusual put option volume: GGPI MQ INDA TRIL
-
Trillium Therapeutics (TRIL) Shareholders Approve Takeover by Pfizer
-
Increasing unusual option volume: TRIL PROG FROG ATER MCFE ISEE
-
Increasing unusual option volume: TRIL GES COMM ACM URBN DKS
-
Stocks with Implied Volatility Movement
-
Increasing unusual option volume: TRIL CARA PANW BXRX
-
Craig-Hallum Downgrades Trillium Therapeutics (TRIL) to Hold
-
Increasing unusual call option volume: TRIL PAGS KDMN AXSM GES COMM CARA FBRX
-
JMP Securities Downgrades Trillium Therapeutics (TRIL) to Market Perform
-
ALX Oncology (ALXO) Gains on Continued CD47 Takeover Activity
-
Increasing unusual option volume: TRIL BEKE MCHI GES FBRX ITW CFLT CARA COMM
-
Increasing unusual option volume: TRIL ITW CFLT CARA COMM
-
Pre-Open Stock Movers 08/23: (TRIL) (XERS) (AXSM) Higher; (LYFT) (UBER) (BGS) Lower (more...)
-
H.C. Wainwright Downgrades Trillium Therapeutics (TRIL) to Neutral
-
Trillium Therapeutics (TRIL) Acquired by Pfizer (PFE) for $2.26B or $18.50/sh
-
Trillium Therapeutics (TRIL) Reports First Patient Dosing in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
-
Benchmark Starts Trillium Therapeutics (TRIL) at Buy
-
Trillium Therapeutics (TRIL) files automatic mixed securities shelf; no amount given
-
Increasing unusual put option volume: QS TRIL UL HCAC CLSK FOXA SBE
-
Trillium Therapeutics (TRIL) 17 calls to 1 put on IV of 150
-
Trillium Therapeutics (TRIL) calls more active than puts
-
Evercore ISI Starts Trillium Therapeutics (TRIL) at Outperform
-
Trillium Therapeutics (TRIL) Receives Notices of Allowance From U.S. Patent and Trademark Office
-
Trillium Therapeutics (TRIL) Announces Michael Kamarck, Ph.D. to Board
-
Trillium Therapeutics (TRIL) Prices 10M Share Common Offering at $13/Sh
-
H.C. Wainwright Upgrades Trillium Therapeutics (TRIL) to Buy
-
Trillium Therapeutics (TRIL) Announces 8.5M Share Proposed Public Offering of Common Shares
-
Pre-Open Stock Movers 09/09: (TRIL) (NLS) (TSLA) Higher; (WORK) (ANTX) (LULU) Lower (more...)
-
Trillium Therapeutics (TRIL) PT Raised to $24 at Ladenburg Thalmann
-
Trillium Therapeutics (TRIL) PT Raised to $14 at JMP Securities
-
After-Hours Movers 09/08: (TRIL) (NVAX) (QRVO) Higher; (WORK) (ATNX) (LULU) Lower (more...)
-
Trillium Therapeutics (TRIL) Announces $25 Million Equity Investment From Pfizer Inc. (PFE)
-
Craig-Hallum Starts Trillium Therapeutics (TRIL) at Buy
-
Jones Trading Starts Trillium Therapeutics (TRIL) at Buy
-
Trillium Therapeutics (TRIL) Reports Update on Ph. I Dose Escalation Study of Its CD47 Blocker TTI-622 at the ASCO20 Virtual Scientific Program
-
JMP Securities Starts Trillium Therapeutics (TRIL) at Market Outperform
-
Trillium Therapeutics (TRIL) Announces $50M ATM Offering
-
Trillium Therapeutics (TRIL) provides update on clinical trial activities and business operations
-
Trillium Therapeutics (TRIL) on Watch on Chatter
-
Trillium Therapeutics (TRIL) PT Raised to $12 at Ladenburg Thalmann
-
Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
-
Trillium Therapeutics (TRIL) Surges as Gilead (GILD) Acquires Forty Seven (FTSV)
-
Trillium Therapeutics (TRIL) to Resume Trading at 1 pm
-
Trillium Therapeutics (TRIL) Responds to Market Activity, Not Aware of Material, Undisclosed Information
-
Trillium Therapeutics (TRIL) Halted, News Pending
-
Pre-Open Stock Movers 02/28: (APT) (SGMO) (FTSV) Higher; (BIG) (W) (BYND) Lower (more...)
-
After-Hours Stock Movers 02/27: (SGMO) (TRIL) (FTSV) Higher; (BIG) (CHRS) (BYND) Lower (more...)
-
Trillium Therapeutics (TRIL) Adds Paul Walker to Board
-
Trillium Therapeutics (TRIL) Announces Pricing of $101.7M Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
Back to TRIL Stock Lookup